Clinical Trials on Esophageal Cancer TNM Staging in Argentina

Total 8 results

Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649)

Gastric Cancer | Esophageal Adenocarcinoma | Gastroesophageal Junction Cancer

United States, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Czechia, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Portugal, Romania, Russian Federation, Si... and more
Daiichi Sankyo
AstraZeneca

Recruiting

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Gastroesophageal Junction Adenocarcinoma | Gastric Cancer, Adenocarcinoma

Hong Kong, Korea, Republic of, France, United Kingdom, Spain, China, Ireland, Brazil, Japan, Singapore, Belgium, Israel, Russian Federation, Argentina, Chile, Hungary, Poland, Portugal, Taiwan, Turkey, Ukraine, Germany, Romania, Italy
Bristol-Myers Squibb

Completed

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Soft Tissue Sarcoma | Transitional Cell Carcinoma | Advanced Non-small Cell Lung Cancer | Gastric/Esophageal Adenocarcinoma | Pancreatic Cancer Including Ampulla of Vater

United States, Argentina, Germany, Belgium, Canada, Poland, Netherlands, United Kingdom, France
Taiho Oncology, Inc.

Terminated

Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial (DIGEST)

Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction

Belgium, Spain, United States, Italy, Estonia, Russian Federation, Bulgaria, Hungary, Croatia, Israel, Mexico, Poland, Portugal, Romania, South Africa, Ukraine, United Kingdom, Brazil, Germany, Argentina
Bayer

Completed

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI

Breast Cancer | Diagnostic Imaging

Italy, Korea, Republic of, Switzerland, Colombia, United States, Brazil, Germany, Finland, Argentina
Amgen

Recruiting

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer (FORTITUDE-102)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States, Israel, Italy, Spain, Switzerland, Canada, Australia, Germany, United Kingdom, Austria, France, Japan, Taiwan, China, Belgium, Poland, Thailand, Czechia, Singapore, Hungary, Argentina, Brazil, Romania, Portuga... and more
Amgen
Zai Lab (China only)

Recruiting

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Canada, Japan, United States, Korea, Republic of, China, Italy, Australia, Sweden, Spain, Taiwan, France, Belgium, Denmark, Thailand, Turkey, Czechia, Bulgaria, Brazil, Norway, Mexico, Poland, Estonia, Israel, Greece, Romania, Chile, Peru, Po... and more
Jazz Pharmaceuticals
BeiGene, Ltd.

Recruiting

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01)

Gastroesophageal Adenocarcinoma | Esophageal Adenocarcinoma | Gastric Neoplasms

Korea, Republic of, Belgium, Japan, China, Netherlands, Spain, Germany, United Kingdom, Malaysia, Portugal, France, Italy, Australia, Taiwan, Turkey, Thailand, Argentina, Mexico, Ireland, Estonia, Serbia, Romania, Canada, Poland, Brazil, ... and more

Clinical Trials on Esophageal Cancer TNM Staging in Argentina

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations